In a preliminary clinical study, the experimental drug daraxonrasib (marketed as Rasonque) produced measurable tumor reductions in more than 30% of participants with non‑small‑cell lung cancer (NSCLC). All patients enrolled in the trial carried a mutation in a member of the RAS family of proteins and had previously received other cancer therapies.
Promising Early Results in Lung Cancer
Researchers reported that the small trial demonstrated tumor shrinkage in a notable portion of the cohort, a result described by thoracic oncologist Kathryn Arbour of Memorial Sloan Kettering Cancer Center as “incredibly promising.” The study, authored by Arbour and colleagues, appeared in the New England Journal of Medicine on 2 September.
Despite the encouraging response rate, the investigators observed that some participants experienced tumor regrowth after an initial period of shrinkage. Arbour noted that the mechanisms behind this resistance are only beginning to be understood.
Molecular Glue Strategy Targets RAS Proteins
RAS proteins are frequently mutated in aggressive cancers, including pancreatic, lung and colorectal tumors. Historically labeled “undruggable,” these proteins have resisted conventional drug design because of the difficulty in blocking their activity directly.
Daraxonrasib, developed by Revolution Medicines in Redwood City, California, employs a novel “molecular glue” approach. The compound first binds to cyclophilin A, a common cellular protein, creating a complex that can attach to both normal and mutant RAS molecules. This binding blocks RAS from interacting with its usual partners, effectively inhibiting the signaling pathways that drive tumor growth.
The strategy proved highly effective in a prior pancreatic cancer trial. In that study of 500 patients with advanced disease, daraxonrasib nearly doubled average survival to 13.2 months compared with 6.7 months for standard chemotherapy. Those outcomes led the U.S. Food and Drug Administration to approve the drug on 26 August, more than six months earlier than anticipated.
Next Steps and Regulatory Outlook
A larger, randomized trial is currently underway to compare daraxonrasib directly with standard chemotherapy in NSCLC patients. Regulators, including the FDA, are expected to require data from this study before considering approval of the drug for lung cancer indications.
The expanded trial will also assess how long the drug’s effects persist before tumors develop resistance, a question highlighted by the early observations of tumor regrowth. Understanding the durability of response is critical for determining the drug’s place in treatment algorithms.
Commenting on the broader implications, cancer researcher Channing Der of the University of North Carolina at Chapel Hill asked, “Of course, everyone is now asking the question: what next? Will this be extended to other cancers?” The ongoing investigation will help answer that question by evaluating whether the molecular glue mechanism can be leveraged against other RAS‑driven malignancies.
As the larger trial progresses, clinicians and patients alike will watch for evidence that the early promise seen in this small lung‑cancer cohort can be replicated on a broader scale, potentially expanding the therapeutic options for cancers historically limited by the difficulty of targeting RAS mutations.
Steve Lopez is a Senior Editorial Columnist and Health & Public Policy reporter for News Raise. Steve focuses on healthcare advancements, medical technologies, and public health policies.
